ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

polyethylene glycol 3350

Also written as “NER1006”, “polyethyleneglycol3350” and “HalfLytely”.

Its studies are mostly in Constipation · Colonic Neoplasms · Opioid-Induced Constipation · Colorectal Neoplasms · Enterocolitis, Pseudomembranous, led by 4 companies.

Drug pagePolyethylene glycol 3350: every studyAll 64 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Sep 7, 200515 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sebela Pharmaceuticals100 open or runningphase 4since Sep 7, 2005Sep 7, 2005none ahead
Bayerits history only30 open or runningphase 4since Oct 9, 2008Oct 9, 2008none ahead
Ascension Healthits history only10 open or runningphase 4since Jun 21, 2012Jun 21, 2012none ahead
Taejoon Pharmaceuticalits history only10 open or runningphase 3since Apr 21, 2023Apr 21, 2023none ahead

Also a collaborator on its studies: Parexel, Quotient Sciences and Pierrel Research Europe.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sebela Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 7, 2005First studies: 6 phase 4 studiesFirst studyNCT00153153, NCT00153140, NCT00153127 and 3 more
  2. Sep 9, 20052 phase 3 studies in ColonoscopyNCT00164164, NCT00164151
  3. Apr 27, 2006Phase 4 study in ConstipationNCT00319670 · 25 enrolled · United States
  4. Dec 20, 2007Phase 4 study in ConstipationNCT00583609 · 20 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 Sebela Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00583609Constipation · United States4CompletedJul 200820
NCT00319670Constipation · United States4CompletedMay 200625
NCT00164177Colonoscopy · United States4CompletedDec 200420
NCT00164164Colonoscopy · United States3CompletedJun 2000200
NCT00164151Colonoscopy · United States3CompletedMay 200260
NCT00164125Constipation · United States4CompletedNov 2004300
NCT00153153Constipation · United States4CompletedDec 2004300
NCT00153140Constipation · United States4CompletedOct 2004239
NCT00153127Constipation · United States4CompletedSep 2004100
NCT00153114Constipation · United States4CompletedSep 2004100

How it is read

Names in the registry

  • “NER1006”, 9 entries
  • “polyethyleneglycol3350”, 5 entries
  • “HalfLytely”, 3 entries
  • “PEG 3350 plus electrolytes”, 2 entries
  • “PLENVU®”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.